Cyrus Harmon Sells 8,256 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 8,256 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total transaction of $77,358.72. Following the transaction, the director now owns 772,277 shares in the company, valued at approximately $7,236,235.49. This trade represents a 1.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Olema Pharmaceuticals Price Performance

OLMA stock opened at $6.72 on Friday. Olema Pharmaceuticals, Inc. has a 52 week low of $6.50 and a 52 week high of $16.77. The company’s 50-day moving average price is $10.80 and its 200 day moving average price is $11.88.

Institutional Trading of Olema Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC lifted its holdings in shares of Olema Pharmaceuticals by 105.0% in the third quarter. Barclays PLC now owns 94,915 shares of the company’s stock valued at $1,133,000 after purchasing an additional 48,614 shares in the last quarter. Conway Capital Management Inc. purchased a new position in shares of Olema Pharmaceuticals during the third quarter valued at approximately $119,000. XTX Topco Ltd lifted its stake in shares of Olema Pharmaceuticals by 103.4% during the third quarter. XTX Topco Ltd now owns 25,332 shares of the company’s stock valued at $302,000 after buying an additional 12,878 shares during the period. EP Wealth Advisors LLC lifted its stake in shares of Olema Pharmaceuticals by 5.2% during the third quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock valued at $581,000 after buying an additional 2,407 shares during the period. Finally, Wellington Management Group LLP increased its position in Olema Pharmaceuticals by 10.8% during the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after purchasing an additional 97,428 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Olema Pharmaceuticals currently has an average rating of “Buy” and an average price target of $27.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.